Key points from article :
Bryan Johnson, the tech entrepreneur turned biohacker, has launched a programme called Immortals that charges $1 million a year to follow the anti-ageing protocol he has tested on himself for five years. Three places are on offer, and an UnHerd analysis argues that buyers may get far less than the price suggests.
Johnson, who sold his payments company Braintree to PayPal for $800 million in 2013, reportedly spends about $2 million a year on his own regimen. It includes more than 100 supplements a day, a strict vegan diet, constant biomarker tracking and a series of experimental treatments, among them plasma exchange and an unapproved gene therapy. He publishes figures claiming his biological age has fallen by more than five years. The Immortals package reportedly adds stem cell injections, plasma exchanges, gene therapies and BryanAI, an AI health coach available around the clock. According to the article, more than 1,500 people applied within the first 30 hours.
The author, historian and journalist Oliver Bateman, questions whether the programme can be trusted. The protocol has a sample size of one and no control group, and because dozens of interventions are combined, it is impossible to tell which of them, if any, produce the claimed results. Immortals has no peer review or regulatory oversight, and Johnson sells supplements himself, which creates a conflict of interest. An independent analysis by Empirical Health found that his core routine could be copied for under $2,000 a year.
Bateman is not entirely dismissive. Because participants fund the programme privately, any useful findings could eventually benefit others at much lower cost. His prediction is that the three winners will mostly pay to learn what the science already says for free: sleep well, eat well, exercise and keep moving.
There are caveats. This is an opinion piece rather than a study, and some of its more striking claims about Johnson's treatments are reported rather than independently verified. Johnson has not published his protocol in a peer-reviewed journal, so neither the benefits nor the risks of the programme can be judged from the available evidence.
The analysis was written by Oliver Bateman and published in UnHerd.


